Pfiz­er vs J&J: Re­searchers are duk­ing it out for the cham­pi­onship ti­tle in non­metasta­t­ic prostate can­cer

Pfiz­er $PFE and J&J $JNJ have come down to the wire with piv­otal da­ta on non­metasta­t­ic prostate can­cer. And there are bil­lions of dol­lars in rev­enue on the line here.

Both com­pa­nies post­ed their ab­stracts be­ing re­viewed at AS­CO’s Gen­i­touri­nary Can­cers Sym­po­sium Mon­day evening. And while sci­en­tists frown on com­par­ing da­ta from two dif­fer­ent stud­ies, you can bet that an­a­lysts will be lin­ing up the re­sults side-by-side to see who will come out ahead.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER